Shaji Kumar, MD, Reviews PFS With Daratumumab-Containing Therapy in Frontline Myeloma

Video

At EHA 2021, Shaji Kumar, MD, reflects on the significance of 5-year data from the MAIA study of a daratumumab combination in patients with multiple myeloma.

CancerNetwork® sat down with Shaji Kumar, MD, of the Mayo Clinic, at the 2021 European Hematology Association (EHA) Congress to talk about the statistically significant improvement in progression-free survival observed when daratumumab (Dazalex) was added to lenalidomide (Revlimid) and dexamethasone (D-Rd) versus the 2-drug combination alone in the phase 3 MAIA trial (NCT02252172).1 Kumar also mentions overall survival being consistent with all the subgroups of patients.

Transcript:

Previous reports of the MAIA study [published] in the New England Journal of Medicine had included the earlier data that showed the significant improvement in progression-free survival and the improved depth of response in the overall response rate with the 3-drug combination compared with the 2-drug combination. Now with longer follow up, we continue to see the significant difference in progression-free survival. In fact, at 16-months, the progression-free survival rate for the daratumumab combination was 52.5% compared with 28.7% for lenalidomide and dexamethasone, so [there was] almost a doubling of the 16-month PFS rate with the [D-Rd] combination.

The initial data that was seen has been confirmed by the longer follow up. And then additionally…overall survival improvement appears to be consistent across all the subgroups of patients, irrespective of the age, baseline renal function, [and International Staging System] stage. The impact of adding daratumumab was less evident in patients with high-risk disease. But again, as data matures, we’ll get a better sense of what this means because only a small proportion of patients are high risk.

References

1. Theirry F, Kumar S, Torben P, et al. Overall survival results with daratumumab, Lenalidomide, and dexamethasone versus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: phase 3 MAIA study. Presented at: 2021 European HematologyAssociation Annual Meeting; June 9-17, 2021; Virtual; Abstract LB1901. Accessed June 29, 2021. https://bit.ly/3hmf7l9

2. Facon T, Kumar S, Plesner T, et al. Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma. N Engl J Med. 2019;380(22):2104-2115. doi:10.1056/NEJMoa1817249

Recent Videos
Data from the phase 3 DeLLphi-304 trial at ASCO 2025 revealed a survival advantage with tarlatamab vs chemotherapy in second-line ES-SCLC.
The FDA approval of tarlatamab in SCLC has received much press attention, according to Daniel R. Carrizosa, MD, MS.
The National ICE-T Conference may inspire future collaboration between community and academic oncologists in the management of different cancers.
One of the largest obstacles to tackle in the kidney cancer landscape will be translating the research on rare kidney cancer subtypes into clinical trials.
Long-term toxicities like infections and secondary primary malignancies remain a concern when sequencing novel agents for those with multiple myeloma.
Zanzalitinib exhibited favorable data when evaluated alone or in combination with anti-PD-1 immune checkpoint inhibition in phase 1 RCC trials.
The investigational agent exhibited superior efficacy vs pembrolizumab in patients with lung cancer, suggesting potential efficacy in kidney cancer.
Management of adverse effects and access to cellular therapies among community oncologists represented key points of discussion in multiple myeloma.
“As a community, if we’re looking to help enroll and advocate for patients with rare [kidney cancers], we need to be aware of what is out there,” said A. Ari Hakimi, MD.
Treatment with the dual inhibitor displayed a short half-life and a manageable toxicity profile in patients with clear cell renal cell carcinoma.
Related Content